| Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma | 09/10 08:30 | seekingalpha.com |
| Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates | 08/08 18:25 | zacks.com |
| FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals | 07/04 14:13 | investorplace.com |
| Arcellx's Strategic Moves With Anito-Cel Aim To Disrupt Myeloma Market | 06/26 11:19 | seekingalpha.com |
| 7 Biotech Stocks to Put on Your Breakthrough Radar | 05/27 12:32 | investorplace.com |
| Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates | 05/09 18:10 | zacks.com |
| Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program | 05/09 16:05 | businesswire.com |
| Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program | 05/09 16:05 | businesswire.com |
| Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine | 05/09 06:49 | investorplace.com |
| Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference | 04/04 16:00 | businesswire.com |